Skip to main content
 
Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

See our updated masking policy »

Stanford Health Care

Myelodysplastic Syndromes, Version 2.2015 JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK Greenberg, P. L., Stone, R. M., Bejar, R., Bennett, J. M., Bloomfield, C. D., Borate, U., De Castro, C. M., Deeg, H. J., DeZern, A. E., Fathi, A. T., Frankfurt, O., Gaensler, K., Garcia-Manero, G., Griffiths, E. A., Head, D., Klimek, V., Komrokji, R., Kujawski, L. A., Maness, L. J., O'Donnell, M. R., Pollyea, D. A., Scott, B., Shami, P. J., Stein, B. L., Westervelt, P., Wheeler, B., Shead, D. A., Smith, C. 2015; 13 (3): 261-272

Abstract

The NCCN Guidelines for Myelodysplastic Syndromes (MDS) comprise a heterogeneous group of myeloid disorders with a highly variable disease course that depends largely on risk factors. Risk evaluation is therefore a critical component of decision-making in the treatment of MDS. The development of newer treatments and the refinement of current treatment modalities are designed to improve patient outcomes and reduce side effects. These NCCN Guidelines Insights focus on the recent updates to the guidelines, which include the incorporation of a revised prognostic scoring system, addition of molecular abnormalities associated with MDS, and refinement of treatment options involving a discussion of cost of care.

View details for Web of Science ID 000350781700004

View details for PubMedID 25736003